Valuable Targets

What are COX-2 inhibitors and how do you quickly get the latest development progress?

23 November 2023
4 min read

COX-2, or cyclooxygenase-2, is an enzyme that plays a crucial role in the human body's inflammatory response. It is responsible for the production of prostaglandins, which are hormone-like substances involved in various physiological processes. Unlike COX-1, which is constitutively expressed in most tissues, COX-2 is primarily induced during inflammation. COX-2 is involved in the synthesis of prostaglandins that mediate pain, fever, and inflammation. However, excessive COX-2 activity can lead to chronic inflammation and contribute to the development of various diseases, including arthritis and certain types of cancer. Therefore, pharmaceutical interventions targeting COX-2 have been developed to regulate inflammation and manage associated conditions

COX-2 inhibitors belong to nonsteroidal anti-inflammatory drugs (NSAIDs), specifically targeting cyclooxygenase-2 (COX-2). As part of the immune response to infection or injury, COX-2 inhibitors help to release prostaglandins (synthesized from arachidonic acid). Prostaglandins play a key role in the inflammatory response. Chronic inflammation may be the source of pain for patients with scleroderma and may lead to permanent damage. By blocking the production of prostaglandins, COX-2 inhibitors can reduce inflammation levels and minimize complications. For patients with scleroderma, these inhibitors can alleviate inflammation-induced swelling, stiffness, and joint pain caused by inflammation.

The analysis of the target COX-2 in the pharmaceutical industry reveals a competitive landscape with multiple companies involved in the development of drugs. Viatris Inc. stands out with the highest stage of development and multiple approved drugs. Pain is the most common indication for approved drugs, indicating a significant focus on addressing pain-related conditions. Small molecule drugs dominate the drug types progressing rapidly, while China and the United States are leading in terms of drug development. The future development of the target COX-2 is promising, with ongoing research and development efforts by various companies and countries/locations.

What is the mechanism of action of COX-2 inhibitors? 

COX-2 inhibitors refer to a class of drugs that specifically target and inhibit the enzyme cyclooxygenase-2 (COX-2). COX-2 is an enzyme involved in the production of prostaglandins, which are chemical messengers that play a role in inflammation, pain, and fever. By inhibiting COX-2, these medications reduce the production of prostaglandins, thereby alleviating pain and inflammation.

From a biomedical perspective, COX-2 inhibitors are commonly used in the treatment of various conditions such as arthritis, menstrual cramps, and acute pain. They are particularly beneficial in cases where inflammation is a major component of the disease process. These drugs are often preferred over non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) because they specifically target COX-2 without significantly inhibiting COX-1, another form of the enzyme that helps protect the stomach lining and maintain kidney function.

It is important to note that while COX-2 inhibitors provide effective pain relief and anti-inflammatory effects, they are not without risks. Prolonged use of these drugs has been associated with an increased risk of cardiovascular events such as heart attack and stroke. Therefore, their use should be carefully considered, and patients with a history of heart disease or stroke may require alternative treatment options. Regular monitoring and close supervision by a healthcare professional are essential when using COX-2 inhibitors.

List of COX-2 Inhibitors

The currently marketed COX-2 inhibitors include:

For more information, please click on the image below.

What is the purpose of using COX-2 inhibitors?

COX-2 Inhibitors are anti-inflammatory agents that can be used to treat symptoms associated with scleroderma, such as joint and tendon pain. For more information, please click on the image below to log in and search.

How to acquire the most recent advancement in COX-2 inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of COX-2 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

Biological Glossary | What is Open Reading Frame (ORF)?
Bio Sequence
2 min read
Biological Glossary | What is Open Reading Frame (ORF)?
23 November 2023
Open reading frame (ORF), in the context of genomics, refers to a section of a DNA sequence that lacks a stop codon and potentially codes for a protein.
Read →
JAMP Pharma and Alvotech have been approved to sell Jamteki (AVT04), the first biosimilar of Stelara® (ustekinumab)
Latest Hotspot
3 min read
JAMP Pharma and Alvotech have been approved to sell Jamteki (AVT04), the first biosimilar of Stelara® (ustekinumab)
23 November 2023
Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.
Read →
An analysis of ENB-003's R&D progress and its clinical results presented at the 2023 SITC
An analysis of ENB-003's R&D progress and its clinical results presented at the 2023 SITC
23 November 2023
The 2023 SITC Congress kicked off with a groundbreaking report on the latest clinical results of ENB-003, establishing a solid foundation for future research.
Read →
How To Obtain Target-Related Sequences Directly Through Target Name And Perform Sequence Alignment?
Bio Sequence
2 min read
How To Obtain Target-Related Sequences Directly Through Target Name And Perform Sequence Alignment?
23 November 2023
This article aims to instruct you on how to swiftly locate related sequences via a simple one-click method, using the target name.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.